The new single-handed inserter with an optimized package secured approval from the US Food and Drug Administration (FDA) in May this year.

LILETTA is a hormone-releasing system, which will be placed in woman's uterus to prevent pregnancy for up to three years.

The approval was granted based on the hormonal IUD trial, which conducted in the US.

The ACCESS IUS (a comprehensive contraceptive efficacy and safety study of an IUS) trial included 1,751 women, who received LILETTA.

According to the company, the study demonstrated to be safe and effective for a range of women, with a cumulative three-year efficacy rate of 99.45%.

Allergan chief R&D officer David Nicholson said: "As a leader in women's healthcare, Allergan is committed to providing our customers with the most efficient technology and support needed to educate their patients about their reproductive health.

"The launch of the LILETTA single-handed inserter continues to demonstrate our commitment to innovation in women's health and serves as another bold example of providing options to better serve our customers and patients."

Medicines360 CEO Dr Jessica Grossman said: "We are excited to bring to market the new LILETTA inserter and anticipate that the single-handed process may lead to broader use by healthcare providers, thereby increasing the number of women who have access to this effective contraceptive.”